Description
Cytomol t (Liothyronine) 25 mcg
Cytomol t is identified here as liothyronine, a synthetic thyroid hormone used in thyroid hormone replacement therapy. Liothyronine is the active T3 form of thyroid hormone and is available in tablet form for oral use.
Active Ingredient and Medicine Class
The verified active ingredient is liothyronine sodium. It is a synthetic thyroid hormone and a prescription endocrine medicine. It is the T3 form of thyroid hormone, which acts more rapidly than thyroxine (T4) after absorption.
Established Medical Uses
Official prescribing information for liothyronine sodium tablets supports its use as thyroid hormone replacement in hypothyroidism. In clinical practice, liothyronine has also been considered in selected patients with persistent symptoms despite levothyroxine treatment, but routine superiority over levothyroxine has not been demonstrated.
How It Works
Liothyronine replaces or supplements thyroid hormone activity by providing T3, the biologically active thyroid hormone. T3 binds to thyroid hormone receptors in tissues and helps regulate energy use, metabolism, heart rate, and many body functions influenced by thyroid hormone.
Important Safety Information
Liothyronine should be used with caution in people with cardiovascular disease, since excess thyroid hormone can strain the heart. Important safety issues include the risk of overtreatment, interaction with medicines that affect thyroid hormone activity, and the need for careful monitoring when thyroid replacement therapy is changed. It is also not a routine substitute for levothyroxine in all patients, and evidence reviews have not shown consistent benefit for combination T4/T3 treatment over T4 alone.
Possible Side Effects
Recognised adverse effects of liothyronine are often those of excess thyroid hormone and may include palpitations, nervousness, tremor, sweating, insomnia, and weight loss. More serious reactions can include arrhythmias or worsening of underlying heart disease, particularly if thyroid hormone levels become too high.
Scientific Evidence
Peer-reviewed reviews and consensus statements report that trials of levothyroxine plus liothyronine have generally not shown consistent superiority over levothyroxine alone for hypothyroidism. A 2023 British consensus statement concluded that liothyronine may be considered only in selected patients with confirmed overt hypothyroidism and persistent symptoms after adequate levothyroxine treatment, with shared decision-making. A 2024 systematic review and meta-analysis likewise found no clear overall advantage of combination therapy.
Medical Information Notice
This page is an educational summary based on sources available at the time of review and does not replace the official patient leaflet or an individual assessment by a qualified healthcare professional.
Medical Sources
- U.S. Food and Drug Administration (FDA) — CYTOMEL (liothyronine sodium) tablets, for oral use
- DailyMed — Liothyronine Sodium Tablet
- Ahluwalia R, et al. “Use of liothyronine (T3) in hypothyroidism: Joint British Thyroid Association/Society for endocrinology consensus statement.” Clinical Endocrinology. 2023. PubMed
